<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1804245174
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2024
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Sudex 200 mg per 2 ml
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        SUGAMMADEX
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        2
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        174.25
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="ASPIRO PHARMA LIMITED" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            ASPIRO PHARMA LIMITED
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2950]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Saudi Amarox
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Saudi Amarox
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        V03AB35
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>When you have some types of operations, your muscles must be completely relaxed. This makes it easier for the surgeon to do the operation. For this, the general anaesthetic you are given includes medicines to make your muscles relax. These are called muscle relaxants, and examples include rocuronium bromide and vecuronium bromide. Because these medicines also make your breathing muscles relax, you need help to breathe (artificial ventilation) during and after your operation until you can breathe on your own again.<br />Sudex is used to speed up the recovery of your muscles after an operation to allow you to breathe on your own again earlier. It does this by combining with the rocuronium bromide or vecuronium&nbsp;bromide in your body. It can be used in adults whenever rocuronium bromide or vecuronium bromide is used and in children and adolescents (aged 2 to 17 years) when rocuronium bromide is used for a moderate level of relaxation.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>You should not be given Sudex<br />&bull; if you are allergic to sugammadex or any of the other ingredients of this medicine (listed in section 6).<br />&rarr; Tell your anaesthetist if this applies to you.<br />Warnings and precautions<br />Talk to your anaesthetist before Sudex is given<br />&bull; if you have kidney disease or had in the past. This is important as Sudex is removed from your body by the kidneys.<br />&bull; if you have liver disease or have had it in the past.<br />&bull; if you have fluid retention (oedema).<br />&bull; if you have diseases which are known to give an increased risk of bleeding (disturbances of blood clotting) or anticoagulation medication.<br />Children and adolescents<br />This medicine is not recommended for infants less than 2 years of age.<br />Other medicines and Sudex<br />&rarr; Tell your anaesthetist if you are taking, have recently taken or might take any other medicines. Sudex may affect other medicines or be affected by them.<br />Some medicines reduce the effect of Sudex<br />&rarr; It is especially important that you tell your anaesthetist if you have recently taken:<br />&bull; toremifene (used to treat breast cancer).<br />&bull; fusidic acid (an antibiotic).<br />Sudex can affect hormonal contraceptives<br />&bull; Sudex can make hormonal contraceptives - including the &lsquo;Pill&rsquo;, vaginal ring, implants or a hormonal IntraUterine System (IUS) - less effective because it reduces how much you get of the progestogen hormone. The amount of progestogen lost by using Sudex is about the same as missing one oral contraceptive Pill.<br />&rarr; If you are taking the Pill on the same day as Sudex is given to you, follow the instructions for a missed dose in the Pill&rsquo;s package leaflet.<br />&rarr; If you are using other hormonal contraceptives (for example a vaginal ring, implant or IUS) you should use an additional non-hormonal contraceptive method (such as a condom) for the next 7 days and follow the advice in the package leaflet.<br />Effects on blood tests<br />In general, Sudex does not have an effect on laboratory tests. However, it may affect the results of a blood test for a hormone called progesterone. Talk to your doctor if your progesterone levels need to be tested on the same day you receive Sudex.<br />Pregnancy and breast-feeding<br />&rarr; Tell your anaesthetist if you are pregnant or might be pregnant or if you are breast-feeding. You may still be given Sudex, but you need to discuss it first.<br />It is not known whether sugammadex can pass into breast milk. Your anaesthetist will help you decide whether to stop breast-feeding, or whether to abstain from sugammadex therapy, considering the benefit of breast-feeding to the baby and the benefit of Sudex to the mother.<br />Driving and using machines<br />Sudex has no known influence on your ability to drive and use machines.<br />Sudex contains sodium<br />This medicine contains up to 9.7 mg sodium (main component of cooking / table salt) in each mL. This is equivalent to 0.5 % of the recommended maximum daily dietary intake of sodium for an adult.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Sudex will be given to you by your anaesthetist, or under the care of your anaesthetist. The dose<br />Your anaesthetist will work out the dose of Sudex you need based on:<br />&bull; your weight<br />&bull; how much the muscle relaxant medicine is still affecting you.<br />The usual dose is 2-4 mg per kg body weight. A dose of 16 mg/kg can be used in adults if urgent recovery from muscle relaxation is needed.<br />The dose of Sudex for children is 2 mg/kg (children and adolescents between 2-17 years old).<br />How Sudex is given<br />Sudex will be given to you by your anaesthetist. It is given as a single injection through an intravenous line.<br />If more Sudex is given to you than recommended<br />As your anaesthetist will be monitoring your condition carefully, it is unlikely that you will be given too much Sudex. But even if this happens, it is unlikely to cause any problems.<br />If you have any further questions on the use of this medicine, ask your anaesthetist or other doctor.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.<br />If these side effects occur while you are under anaesthesia, they will be seen and treated by your anaesthetist.<br />Common side effects (may affect up to 1 in 10 people)<br />&bull; Cough<br />&bull; Airway difficulties that may include coughing or moving as if you are waking or taking a breath<br />&bull; Light anaesthesia - you may start to come out of deep sleep, so need more anaesthesia. This might cause you to move or cough at the end of the operation<br />&bull; Complications during your procedure such as changes in heart rate, coughing or moving<br />&bull; Decreased blood pressure due to the surgical procedure<br />Uncommon side effects (may affect up to 1 in 100 people)<br />&bull; Shortness of breath due to muscle cramps of the airways (bronchospasm) occurred in patients with a history of lung problems<br />&bull; Allergic (drug hypersensitivity) reactions - such as a rash, red skin, swelling of your tongue and/or throat, shortness of breath, changes in blood pressure or heart rate, sometimes resulting in a serious decrease of blood pressure. Severe allergic or allergic-like reactions can be life threatening. Allergic reactions were reported more commonly in healthy, conscious volunteers<br />&bull; Return of muscle relaxation after the operation<br />Frequency not known<br />&bull; Severe slowing of the heart and slowing of the heart up to cardiac arrest may occur when Sugammadex Injection is administered</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; Store below 30&deg;C.<br />&bull; Keep out of reach of children.<br />&bull; Do not use this medicine after the expiry date which is stated on the pack after EXP. The expiry date refers to the last day of the month.<br />&bull; Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.<br />&bull; After first opening and dilution, store at 2 to 8&deg;C and use within 24 hours.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What Sudex contains<br />The active substance is Sugammadex.<br />Sudex 200mg/2mL:<br />Each mL contains 100 mg of Sugammadex which is equivalent to 108.8 mg of Sugammadex Sodium. The other ingredients are: Sodium Hydroxide, Hydrochloric acid and water for injection.<br />Sudex 500mg/5mL:<br />Each mL contains 100 mg of Sugammadex which is equivalent to 108.8 mg of Sugammadex Sodium. The other ingredients are: Sodium Hydroxide, Hydrochloric acid and water for injection.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Sudex 200mg/2mL
A clear colorless to slightly yellow-brown color solution in 2mL clear lyo bottom tubular glass vial, USP type-I stoppered with 13mm serum GCB rubber stopper and sealed with 13mm flip off seal.
Sudex 500mg/5mL
A clear colorless to slightly yellow-brown color solution in 5mL clear lyo bottom tubular glass vial, USP type-I stoppered with 20mm serum GCB rubber stopper and sealed with 20mm flip off seal.

How supplied:
Sudex Injections are supplied in Tubular glass Vials. Sudex 200mg/2mL - Box of 1 Vial (1x 2mL) Sudex 500mg/5mL - Box of 1 Vial (1x 5mL)
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Aljameah Street, Malaz District<br />Riyadh 12629, Saudi Arabia<br />Tel: +966 11 226 8850<br />Manufacturer:<br />M/s Aspiro Pharma Limited, India</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Last revised in September 2022, Version 1
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>ما هو </strong><strong>سودكس</strong></p><p dir="RTL">يحتوي سودكس على المادة الفعالة سوغاماداكس. يعتبر سودكس عامل ارتباط انتقائي مرخٍ لأنه لا يعمل إلا مع مرخيات عضلات معينة ، روكورونيوم بروميد أو فيكورونيوم البروميد.</p><p dir="RTL"><strong>ما هي دواعي استعمال</strong><strong> </strong><strong>سودكس</strong></p><p dir="RTL">عندما يكون لديك بعض أنواع العمليات الجراحية ، يجب أن تكون عضلاتك مسترخية تمامًا. هذا يسهل على الجراح إجراء العملية. لهذا ، فإن المخدر العام الذي يتم إعطاؤه يشمل الأدوية التي تجعل عضلاتك تسترخي. هذه تسمى مرخيات العضلات ، ومن الأمثلة على ذلك الروكورونيوم بروميد و فيكورونيوم بروميد. نظرًا لأن هذه الأدوية تجعل عضلات التنفس تسترخي أيضًا ، فأنت بحاجة إلى المساعدة في التنفس (التهوية الاصطناعية) أثناء وبعد العملية حتى تتمكن من التنفس بمفردك مرة أخرى.</p><p dir="RTL">يستخدم سودكس لتسريع استعادة استرخاء عضلاتك بعد العملية للسماح لك بالتنفس بالإعتماد على النفس. يقوم بذلك عن طريق الإرتباط مع روكورونيوم بروميد أو فيكورونيوم البروميد في جسمك. يمكن استخدامه للبالغين عند استخدام روكورونيوم بروميد أو فيكورونيوم البروميد وفي الأطفال والمراهقين (الذين تتراوح أعمارهم بين 2 إلى 17 عامًا) عند استخدام روكورونيوم بروميد أو فيكورونيوم البروميد وذلك لاستعادة مستوى استرخاء العضلات إلى المعدل الطبيعي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تستخدم سودكس</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسية تجاه سوغاماداكس أو أي من المكونات الأخرى لهذا الدواء (المدرجة في القسم 6).</p><p dir="RTL">&larr; أخبر طبيب التخدير إذا كان هذا ينطبق عليك.</p><p dir="RTL"><strong>التحزيرات والإحتياطات</strong></p><p dir="RTL">تحدث إلى طبيب التخدير الخاص بك قبل إعطاءك سودكس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك حاليا مرض في الكلى أو عانيت منه في الماضي. هذا مهم حيث يتم إخراج مادة سودكس من جسمك عن طريق الكلى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك مرض كبدي أو عانيت منه في الماضي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من احتباس السوائل (وذمة).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من أمراض معروف عنها أنها تزيد من مخاطر حدوث نزيف (اضطرابات تخثر الدم) أو أدوية مضادة لتخثر الدم.</p><p dir="RTL"><strong>الأطفال و المراهقين</strong></p><p dir="RTL">لا ينصح بهذا الدواء للرضع الذين تقل أعمارهم عن سنتين.</p><p dir="RTL"><strong>الأدوية الأخرى و</strong><strong> </strong><strong>سودكس</strong></p><p dir="RTL">&larr; أخبر طبيب التخدير إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أي أدوية أخرى.</p><p dir="RTL">قد يؤثر سودكس على أدوية أخرى أو يتأثر بها.</p><p dir="RTL"><strong>بعض الأدوية تقلل من تأثير سودكس</strong></p><p dir="RTL">&larr; من المهم بشكل خاص أن تخبر طبيب التخدير إذا كنت قد تناولت مؤخرًا:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; توريميفين (يستخدم لعلاج سرطان الثدي).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمض الفيوسيديك (مضاد حيوي).</p><p dir="RTL"><strong>يمكن أن يؤثر سودكس على موانع الحمل الهرمونية</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكن أن يقلل سودكس من فعالية موانع الحمل الهرمونية - بما في ذلك &quot;حبوب منع الحمل&quot; أو الحلقة المهبلية أو الغرسات أو جهاز اللولب الرحمي الهرموني (IUS) - لأنه يقلل مقدار هرمون البروجستيرون الذي تحصل عليه. كمية البروجستيرون المفقودة باستخدام سودكس هي نفس كمية حبوب منع الحمل المفقودة عن طريق الفم.</p><p dir="RTL">&larr; إذا كنت تتناول حبوب منع الحمل في نفس يوم إعطاء سودكس لك ، فاتبع التعليمات الخاصة بالجرعة الفائتة في نشرة عبوة حبوب منع الحمل.</p><p dir="RTL">&larr; إذا كنت تستخدم وسائل منع حمل هرمونية أخرى (على سبيل المثال حلقة مهبلية أو غرسة أو اللولب الهرموني (IUS)) ، يجب عليك استخدام وسيلة إضافية لمنع الحمل غير الهرمونية (مثل الواقي الذكري) خلال الأيام السبعة التالية واتباع النصائح الواردة في نشرة العبوة.</p><p dir="RTL"><strong>التأثيرات على تحاليل الدم</strong></p><p dir="RTL">بشكل عام ، لا يؤثر سودكس على نتائج الاختبارات المعملية. ومع ذلك ، قد يؤثر على نتائج فحص الدم لهرمون يسمى البروجسترون. تحدث إلى طبيبك إذا كانت مستويات البروجسترون لديك بحاجة إلى اختبار في نفس اليوم الذي تتلقى فيه سودكس.</p><p dir="RTL"><strong>الحمل والرضاعة</strong></p><p dir="RTL">إذا كنت حاملاً أو مرضعة ، أو تعتقدين أنك حامل ، أو تخططين لإنجاب طفل ، فاسألي طبيبك للحصول على المشورة قبل تناول هذا الدواء. يمكن استخدام سوغاماداكس أثناء الحمل ، فقط إذا اعتبره طبيبك ضروريًا بعد التقييم الدقيق.</p><p dir="RTL">&larr; أخبري طبيب التخدير إذا كنت حاملاً أو قد تكونين حاملاً أو مرضعة.</p><p dir="RTL">قد لا يزال يتم إعطاؤك سودكس ، لكن عليك مناقشته أولاً.</p><p dir="RTL">من غير المعروف ما إذا كان سوغاماداكس يمكن أن ينتقل إلى حليب الثدي. سيساعدك طبيب التخدير في تحديد ما إذا كنت ستتوقف عن الرضاعة الطبيعية ، أو الامتناع عن العلاج بالسوغاماداكس ، مع الأخذ في الاعتبار فائدة الرضاعة الطبيعية للطفل وفائدة سودكس للأم.</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">ليس لـ سودكس أي تأثير معروف على قدرتك على القيادة واستخدام الآلات.</p><p dir="RTL"><strong>محتوى سودكس من الصوديوم</strong></p><p dir="RTL">يحتوي هذا الدواء على ما يصل إلى 9.7 ملجرام صوديوم في كل مل (المكون الرئيسي لملح الطعام). هذا يعادل 0.5٪ من الحد الأقصى الموصى به من المدخول الغذائي اليومي من الصوديوم للشخص البالغ.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>1.&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>طريقة استخدام سودكس </strong></p><p dir="RTL">سيعطيك طبيب التخدير سودكس أو تحت رعاية طبيب التخدير.</p><p dir="RTL"><strong>الجرعة</strong></p><p dir="RTL">سيحدد طبيب التخدير جرعة سودكس التي تحتاجها بناءً على:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وزنك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مدى تأثير دواء إرخاء العضلات عليك.</p><p dir="RTL">الجرعة المعتادة هي 2-4 ملجرام لكل كيلوجرام من وزن الجسم. يمكن استخدام جرعة 16 ملجرام / كغم للبالغين إذا كانت هناك حاجة إلى التعافي العاجل من ارتخاء العضلات.</p><p dir="RTL">جرعة سودكس للأطفال هي 2 ملجرام / كغم (للأطفال والمراهقين الذين تتراوح أعمارهم بين 2-17 سنة).</p><p dir="RTL"><strong>كيف يتم إعطاء </strong><strong>سودكس</strong></p><p dir="RTL">سيعطيك طبيب التخدير سودكس. يتم إعطاؤه كحقنة واحدة من خلال أنبوب وريدي.</p><p dir="RTL"><strong>إذا تم إعطاؤك المزيد من سودكس أكثر من الموصى به</strong></p><p dir="RTL">نظرًا لأن طبيب التخدير الخاص بك سيراقب حالتك بعناية ، فمن غير المرجح أن يتم إعطاؤك الكثير من سودكس. ولكن حتى لو حدث هذا ، فمن غير المرجح أن يسبب أي مشاكل.</p><p dir="RTL">إذا كان لديك أي أسئلة أخرى حول استخدام هذا الدواء ، اسأل طبيب التخدير الخاص بك أو طبيب آخر.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية ، يمكن أن يسبب هذا الدواء آثارًا جانبية ، على الرغم من عدم حدوثها لدى الجميع.</p><p dir="RTL">إذا حدثت هذه الآثار الجانبية أثناء وجودك تحت تأثير التخدير ، فسوف يراها طبيب التخدير ويعالجها.</p><p dir="RTL"><strong>أعراض جانبية شائعة (قد تظهر لدى حتى 1 من كل 10 أشخاص)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سعال</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبات في مجرى الهواء والتي قد تشمل السعال أو الحركة كما لو كنت تستيقظ أو تأخذ نفسًا</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التخدير الخفيف - قد تبدأ في الخروج من نوم عميق ، لذلك تحتاج إلى مزيد من التخدير. قد يتسبب ذلك في تحركك أو سعال في نهاية العملية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المضاعفات أثناء العملية الجراحية مثل التغيرات في معدل ضربات القلب أو السعال أو الحركة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض ضغط الدم نتيجة العملية الجراحية</p><p dir="RTL"><strong>أعراض جانبية غير شائعة (قد تظهر لدى حتى 1 من كل 100 شخص)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق في التنفس بسبب تقلصات عضلية في الشعب الهوائية (تشنج قصبي) حدث في المرضى الذين لديهم تاريخ من مشاكل الرئة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات الحساسية (فرط الحساسية للأدوية) - مثل الطفح الجلدي ، احمرار الجلد ، انتفاخ اللسان و / أو الحلق ، ضيق التنفس ، تغيرات في ضغط الدم أو معدل ضربات القلب ، مما يؤدي في بعض الأحيان إلى انخفاض خطير في ضغط الدم. يمكن أن تكون الحساسية الشديدة أو ردود الفعل الشبيهة بالحساسية مهددة للحياة. تم الإبلاغ عن تفاعلات الحساسية بشكل أكثر شيوعًا لدى المتطوعين الصحيين والواعين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عودة ارتخاء العضلات بعد العملية</p><p dir="RTL"><strong>أعراض جانبية غير معروف معدلاتها</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يحدث تباطؤ شديد في القلب وتباطؤ في القلب حتى السكتة القلبية عند إعطاء حقنة سوغاماداكس</p><p><strong>الإبلاغ عن الآثار الجانبية: </strong></p><p dir="RTL">إن كان لديك أعراض جانبية أو لاحظت أعراض جانبية غير مذكورة في هذه النشرة، فضلًا ابلغ الطبيب أوالصيدلي</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>1.&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>&nbsp;</strong><strong>كيفية تخزين </strong><strong>سودكس</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ في درجة حرارة أقل من 30 درجة مئوية.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احفظ هذا الدواء بعيدًا عن رؤية ومتناول أيدي الأطفال.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على العبوة بعد EXP. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من الشهر.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تتخلص من الأدوية في مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. ستساعد هذه الإجراءات في حماية البيئة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعد الفتح والتخفيف لأول مرة ، يُحفظ في درجة حرارة من 2 إلى 8 درجات مئوية ويُستعمل خلال 24 ساعة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة هي سوغاماداكس.</p><p dir="RTL"><strong>سودكس 200 ملجرام / 2 مل:</strong></p><p dir="RTL">يحتوي كل مل على 100 ملجرام من سوغاماداكس وهو ما يعادل 108.8 ملجرام من سوغاماداكس الصوديوم.</p><p dir="RTL">الصواغات الأخرى هي: هيدروكسيد الصوديوم وحمض الهيدروكلوريك وماء للحقن.</p><p dir="RTL"><strong>سودكس 500 ملجرام / 5 مل:</strong></p><p dir="RTL">يحتوي كل مل على 100 ملجرام من سوغاماداكس وهو ما يعادل 108.8 ملجرام من سوغاماداكس الصوديوم.</p><p dir="RTL">الصواغات الأخرى هي: هيدروكسيد الصوديوم وحمض الهيدروكلوريك وماء للحقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>سودكس 200 ملجرام / 2 مل:</strong></p><p dir="RTL">محلول شفاف عديم اللون إلى أصفر-المائل قليلاً إلى البني في قنينة زجاجية أنبوبية سعة 2 مل ، مغلقه بسدادة مطاطية 13 مم متوافقة مع دستور الأدوية الأمريكي من النوع I (GCB ) وغطاء حماية من الألومنيوم قابل للطيّ 13 مم.</p><p dir="RTL"><strong>سودكس 500 ملجرام / 5 مل:</strong></p><p dir="RTL">محلول شفاف عديم اللون إلى أصفر-المائل قليلاً إلى البني في قنينة زجاجية أنبوبية سعة 5 مل ، مغلقه بسدادة مطاطية 20 مم متوافقة مع دستور الأدوية الأمريكي من النوع I (GCB ) وغطاء حماية من الألومنيوم قابل للطيّ 20 مم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><strong>&nbsp;</strong></p><p dir="RTL"><strong>شركة اماروكس السعودية الصناعية</strong></p><p>شارع الجامعة، حي الملز</p><p>الرياض 12629 ، المملكة العربية السعودية</p><p dir="RTL">تليفون: +966 11 226 8850</p><p dir="RTL"><strong>الشركة المصنعة: </strong></p><p>&nbsp;&nbsp; اسبيرو فارما المحدودة, الهند</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة في سبتمير 2022 ، نسخة 1 
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Sudex (Sugammadex Injection 200mg/2mL and 500mg/5mL (100mg/mL))
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Sudex (Sugammadex Injection 200mg/2mL (100mg/mL))
Each mL contains 100 mg of Sugammadex which is equivalent to 108.8 mg of Sugammadex
Sodium.
Sudex (Sugammadex Injection 500mg/5mL (100mg/mL))
Each mL contains 100 mg of Sugammadex which is equivalent to 108.8 mg of Sugammadex
Sodium.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for injection (injection)
Sudex (Sugammadex Injection 200mg/2mL (100mg/mL))
A clear colorless to slightly yellow-brown color solution in 2mL clear lyo bottom tubular glass
vial, USP type-I stoppered with 13mm serum GCB rubber stopper and sealed with 13mm flip off
seal.
Sudex (Sugammadex Injection 500mg/5mL (100mg/mL))
A clear colorless to slightly yellow-brown color solution in 5mL clear lyo bottom tubular glass
vial, USP type-I stoppered with 20mm serum GCB rubber stopper and sealed with 20mm flip off
seal
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults.<br />For the paediatric population: sugammadex is only recommended for routine reversal of<br />rocuronium induced blockade in children and adolescents aged 2 to 17 years.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Posology<br />Sugammadex should only be administered by, or under the supervision of an anaesthetist.</p><p>The use of an appropriate neuromuscular monitoring technique is recommended to monitor the<br />recovery of neuromuscular blockade (see section 4.4).<br />The recommended dose of sugammadex depends on the level of neuromuscular blockade to be<br />reversed.<br />The recommended dose does not depend on the anaesthetic regimen.<br />Sugammadex can be used to reverse different levels of rocuronium or vecuronium induced<br />neuromuscular blockade:<br />Adults<br />Routine reversal:<br />A dose of 4 mg/kg sugammadex is recommended if recovery has reached at least 1-2 post-tetanic<br />counts (PTC) following rocuronium or vecuronium induced blockade. Median time to recovery<br />of the T4/T1 ratio to 0.9 is around 3 minutes (see section 5.1).<br />A dose of 2 mg/kg sugammadex is recommended, if spontaneous recovery has occurred up to at<br />least the reappearance of T2 following rocuronium or vecuronium induced blockade. Median<br />time to recovery of the T4/T1 ratio to 0.9 is around 2 minutes (see section 5.1).<br />Using the recommended doses for routine reversal will result in a slightly faster median time to<br />recovery of the T4/T1 ratio to 0.9 of rocuronium when compared to vecuronium induced<br />neuromuscular blockade (see section 5.1).<br />Immediate reversal of rocuronium-induced blockade:<br />If there is a clinical need for immediate reversal following administration of rocuronium a dose<br />of 16 mg/kg sugammadex is recommended. When 16 mg/kg sugammadex is administered 3<br />minutes after a bolus dose of 1.2 mg/kg rocuronium bromide, a median time to recovery of the<br />T4/T1 ratio to 0.9 of approximately 1.5 minutes can be expected (see section 5.1).<br />There is no data to recommend the use of sugammadex for immediate reversal following<br />vecuronium induced blockade.<br />Re-administration of sugammadex:<br />In the exceptional situation of recurrence of neuromuscular blockade post-operatively (see<br />section 4.4) after an initial dose of 2 mg/kg or 4 mg/kg sugammadex, a repeat dose of 4 mg/kg</p><p>sugammadex is recommended. Following a second dose of sugammadex, the patient should be<br />closely monitored to ascertain sustained return of neuromuscular function.<br />Re-administration of rocuronium or vecuronium after sugammadex:<br />For waiting times for re-administration of rocuronium or vecuronium after reversal with<br />sugammadex, see section 4.4.<br />Additional information on special population<br />Renal impairment:<br />The use of sugammadex in patients with severe renal impairment (including patients requiring<br />dialysis (CrCl &lt; 30 mL/min)) is not recommended (see section 4.4).<br />Studies in patients with severe renal impairment do not provide sufficient safety information to<br />support the use of sugammadex in these patients (see also section 5.1).<br />For mild and moderate renal impairment (creatinine clearance &ge; 30 and &lt; 80 mL/min): the dose<br />recommendations are the same as for adults without renal impairment.<br />Elderly patients:<br />After administration of sugammadex at reappearance of T2 following a rocuronium induced<br />blockade, the median time to recovery of the T4/T1 ratio to 0.9 in adults (18-64 years) was 2.2<br />minutes, in elderly adults (65-74 years) it was 2.6 minutes and in very elderly adults (75 years or<br />more) it was 3.6 minutes. Even though the recovery times in elderly tend to be slower, the same<br />dose recommendation as for adults should be followed (see section 4.4).<br />Obese patients:<br />In obese patients, including morbidly obese patients (body mass index &ge; 40 kg/m2), the dose of<br />sugammadex should be based on actual body weight. The same dose recommendations as for<br />adults should be followed.<br />Hepatic impairment:<br />Studies in patients with hepatic impairment have not been conducted. Caution should be<br />exercised when considering the use of sugammadex in patients with severe hepatic impairment<br />or when hepatic impairment is accompanied by coagulopathy (see section 4.4).<br />For mild to moderate hepatic impairment: as sugammadex is mainly excreted renally no dose<br />adjustments are required.</p><p>Paediatric population<br />Children and adolescents (2-17 years):<br />Sudex 100 mg/mL may be diluted to 10 mg/mL to increase the accuracy of dosing in the<br />paediatric population (see section 6.6).<br />Routine reversal:<br />A dose of 4 mg/kg sugammadex is recommended for reversal of rocuronium induced blockade if<br />recovery has reached at least 1-2 PTC.<br />A dose of 2 mg/kg is recommended for reversal of rocuronium induced blockade at reappearance<br />of T2 (see section 5.1).<br />Immediate reversal:<br />Immediate reversal in children and adolescents has not been investigated.<br />Term newborn infants and infants:<br />There is only limited experience with the use of sugammadex in infants (30 days to 2 years), and<br />term newborn infants (less than 30 days) have not been studied. The use of sugammadex in term<br />newborn infants and infants is therefore not recommended until further data become available.<br />Method of administration<br />Sugammadex should be administered intravenously as a single bolus injection. The bolus<br />injection should be given rapidly, within 10 seconds, into an existing intravenous line (see<br />section 6.6). Sugammadex has only been administered as a single bolus injection in clinical<br />trials</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>As is normal post-anaesthetic practice following neuromuscular blockade, it is recommended to<br />monitor the patient in the immediate post-operative period for untoward events including<br />recurrence of neuromuscular blockade.<br />Monitoring respiratory function during recovery:<br />Ventilatory support is mandatory for patients until adequate spontaneous respiration is restored<br />following reversal of neuromuscular blockade. Even if recovery from neuromuscular blockade is&nbsp;</p><p>complete, other medicinal products used in the peri- and post-operative period could depress<br />respiratory function and therefore ventilatory support might still be required.<br />Should neuromuscular blockade reoccur following extubation, adequate ventilation should be<br />provided.<br />Recurrence of neuromuscular blockade:<br />In clinical studies with subjects treated with rocuronium or vecuronium, where sugammadex was<br />administered using a dose labelled for the depth of neuromuscular blockade, an incidence of<br />0.20% was observed for recurrence of neuromuscular blockade as based on neuromuscular<br />monitoring or clinical evidence. The use of lower than recommended doses may lead to an<br />increased risk of recurrence of neuromuscular blockade after initial reversal and is not<br />recommended (see section 4.2 and section 4.8).<br />Effect on haemostasis:<br />In a study in volunteers doses of 4 mg/kg and 16 mg/kg of sugammadex resulted in maximum<br />mean prolongations of the activated partial thromboplastin time (aPTT) by 17 and 22%<br />respectively and prothrombin time international normalized ratio [PT(INR)] by 11 and 22%<br />respectively. These limited mean aPTT and PT(INR) prolongations were of short duration (&le; 30<br />minutes). Based on the clinical data-base (N=3,519) and on a specific study in 1184 patients<br />undergoing hip fracture/major joint replacement surgery there was no clinically relevant effect of<br />sugammadex 4 mg/kg alone or in combination with anticoagulants on the incidence of peri- or<br />post-operative bleeding complications.<br />In in vitro experiments a pharmacodynamic interaction (aPTT and PT prolongation) was noted<br />with vitamin K antagonists, unfractionated heparin, low molecular weight heparinoids,<br />rivaroxaban and dabigatran. In patients receiving routine post-operative prophylactic<br />anticoagulation this pharmacodynamic interaction is not clinically relevant. Caution should be<br />exercised when considering the use of sugammadex in patients receiving therapeutic<br />anticoagulation for a pre-existing or co-morbid condition.<br />An increased risk of bleeding cannot be excluded in patients:<br />&bull; with hereditary vitamin K dependent clotting factor deficiencies;<br />&bull; with pre-existing coagulopathies;</p><p>on coumarin derivates and at an INR above 3.5;<br />&bull; using anticoagulants who receive a dose of 16 mg/kg sugammadex.<br />If there is a medical need to give sugammadex to these patients the anaesthesiologist needs to<br />decide if the benefits outweigh the possible risk of bleeding complications taking into<br />consideration the patients history of bleeding episodes and type of surgery scheduled. If<br />sugammadex is administered to these patients monitoring of haemostasis and coagulation<br />parameters is recommended.<br />Waiting times for re-administration with neuromuscular blocking agents after reversal with<br />sugammadex:<br />Table 1: Re-administration of rocuronium or vecuronium after routine reversal (up to 4<br />mg/kg sugammadex):<br />Minimum waiting time NMBA and dose to be administered<br />5 minutes 1.2 mg/kg rocuronium<br />4 hours 0.6 mg/kg rocuronium or<br />0.1 mg/kg vecuronium<br />The onset of neuromuscular blockade may be prolonged up to approximately 4 minutes, and the<br />duration of neuromuscular blockade may be shortened up to approximately 15 minutes after readministration<br />of rocuronium 1.2 mg/kg within 30 minutes after sugammadex administration.<br />Based on PK modelling the recommended waiting time in patients with mild or moderate renal<br />impairment for re-use of 0.6 mg/kg rocuronium or 0.1 mg/kg vecuronium after routine reversal<br />with sugammadex should be 24 hours. If a shorter waiting time is required, the rocuronium dose<br />for a new neuromuscular blockade should be 1.2 mg/kg.<br />Re-administration of rocuronium or vecuronium after immediate reversal (16 mg/kg<br />sugammadex):<br />For the very rare cases where this might be required, a waiting time of 24 hours is suggested.<br />If neuromuscular blockade is required before the recommended waiting time has passed, a<br />nonsteroidal neuromuscular blocking agent should be used. The onset of a depolarizing<br />neuromuscular blocking agent might be slower than expected, because a substantial fraction of<br />postjunctional nicotinic receptors can still be occupied by the neuromuscular blocking agent.</p><p>Renal impairment:<br />Sugammadex is not recommended for use in patients with severe renal impairment, including<br />those requiring dialysis (see section 5.1).<br />Light anaesthesia:<br />When neuromuscular blockade was reversed intentionally in the middle of anaesthesia in clinical<br />trials, signs of light anaesthesia were noted occasionally (movement, coughing, grimacing and<br />suckling of the tracheal tube).<br />If neuromuscular blockade is reversed, while anaesthesia is continued, additional doses of<br />anaesthetic and/or opioid should be given as clinically indicated.<br />Marked bradycardia:<br />In rare instances, marked bradycardia has been observed within minutes after the administration<br />of sugammadex for reversal of neuromuscular blockade. Bradycardia may occasionally lead to<br />cardiac arrest. (See section 4.8). Patients should be closely monitored for hemodynamic changes<br />during and after reversal of neuromuscular blockade. Treatment with anti-cholinergic agents<br />such as atropine should be administered if clinically significant bradycardia is observed.<br />Hepatic impairment:<br />Sugammadex is not metabolised nor excreted by the liver; therefore dedicated studies in patients<br />with hepatic impairment have not been conducted. Patients with severe hepatic impairment<br />should be treated with great caution. In case hepatic impairment is accompanied by coagulopathy<br />see the information on the effect on haemostasis.<br />Use in Intensive Care Unit (ICU):<br />Sugammadex has not been investigated in patients receiving rocuronium or vecuronium in the<br />ICU setting.<br />Use for reversal of neuromuscular blocking agents other than rocuronium or vecuronium:<br />Sugammadex should not be used to reverse block induced by nonsteroidal neuromuscular<br />blocking agents such as succinylcholine or benzylisoquinolinium compounds.<br />Sugammadex should not be used for reversal of neuromuscular blockade induced by steroidal<br />neuromuscular blocking agents other than rocuronium or vecuronium, since there are no efficacy&nbsp;</p><p>and safety data for these situations. Limited data are available for reversal of pancuronium<br />induced blockade, but it is advised not to use sugammadex in this situation.<br />Delayed recovery:<br />Conditions associated with prolonged circulation time such as cardiovascular disease, old age<br />(see section 4.2 for the time to recovery in elderly), or oedematous state (e.g., severe hepatic<br />impairment) may be associated with longer recovery times.<br />Drug hypersensitivity reactions:<br />Clinicians should be prepared for the possibility of drug hypersensitivity reactions (including<br />anaphylactic reactions) and take the necessary precautions (see section 4.8).<br />Sodium:<br />This medicinal product contains up to 9.7 mg sodium per mL, equivalent to 0.5 % of the WHO<br />recommended maximum daily intake of 2 g sodium for an adult.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>information in this section is based on binding affinity between sugammadex and other<br />medicinal products, non-clinical experiments, clinical studies and simulations using a model<br />taking into account the pharmacodynamic effect of neuromuscular blocking agents and the<br />pharmacokinetic interaction between neuromuscular blocking agents and sugammadex. Based on<br />these data, no clinically significant pharmacodynamic interaction with other medicinal products<br />is expected, with exception of the following:<br />For toremifene and fusidic acid displacement interactions could not be excluded (no clinically<br />relevant capturing interactions are expected).<br />For hormonal contraceptives a clinically relevant capturing interaction could not be excluded (no<br />displacement interactions are expected).<br />Interactions potentially affecting the efficacy of sugammadex (displacement interactions):<br />Due to the administration of certain medicinal products after sugammadex, theoretically<br />rocuronium or vecuronium could be displaced from sugammadex. As a result recurrence of<br />neuromuscular blockade might be observed. In this situation the patient must be ventilated.<br />Administration of the medicinal product which caused displacement should be stopped in case of<br />an infusion. In situations when potential displacement interactions can be anticipated, patients</p><p>should be carefully monitored for signs of recurrence of neuromuscular blockade (approximately<br />up to 15 minutes) after parenteral administration of another medicinal product occurring within a<br />period of 7.5 hours after sugammadex administration.<br />Toremifene:<br />For toremifene, which has a relatively high binding affinity for sugammadex and for which<br />relatively high plasma concentrations might be present, some displacement of vecuronium or<br />rocuronium from the complex with sugammadex could occur. Clinicians should be aware that<br />the recovery of the T4/T1 ratio to 0.9 could therefore be delayed in patients who have received<br />toremifene on the same day of the operation.<br />Intravenous administration of fusidic acid:<br />The use of fusidic acid in the pre-operative phase may give some delay in the recovery of the<br />T4/T1 ratio to 0.9. No recurrence of neuromuscular blockade is expected in the post-operative<br />phase, since the infusion rate of fusidic acid is over a period of several hours and the blood levels<br />are cumulative over 2-3 days. For re-administration of sugammadex see section 4.2.<br />Interactions potentially affecting the efficacy of other medicinal products (capturing<br />interactions):<br />Due to the administration of sugammadex, certain medicinal products could become less<br />effective due to a lowering of the (free) plasma concentrations. If such a situation is observed,<br />the clinician is advised to consider the re-administration of the medicinal product, the<br />administration of a therapeutically equivalent medicinal product (preferably from a different<br />chemical class) and/or non-pharmacological interventions as appropriate.<br />Hormonal contraceptives:<br />The interaction between 4 mg/kg sugammadex and a progestogen was predicted to lead to a<br />decrease in progestogen exposure (34% of AUC) similar to the decrease seen when a daily dose<br />of an oral contraceptive is taken 12 hours too late, which might lead to a reduction in<br />effectiveness. For oestrogens, the effect is expected to be lower. Therefore the administration of<br />a bolus dose of sugammadex is considered to be equivalent to one missed daily dose of oral<br />contraceptive steroids (either combined or progestogen only). If sugammadex is administered at<br />the same day as an oral contraceptive is taken reference is made to missed dose advice in the&nbsp;package leaflet of the oral contraceptive. In the case of non-oral hormonal contraceptives, the<br />patient must use an additional non hormonal contraceptive method for the next 7 days and refer<br />to the advice in the package leaflet of the product.<br />Interactions due to the lasting effect of rocuronium or vecuronium:<br />When medicinal products which potentiate neuromuscular blockade are used in the postoperative<br />period special attention should be paid to the possibility of recurrence of<br />neuromuscular blockade. Please refer to the package leaflet of rocuronium or vecuronium for a<br />list of the specific medicinal products which potentiate neuromuscular blockade. In case<br />recurrence of neuromuscular blockade is observed, the patient may require mechanical<br />ventilation and re-administration of sugammadex (see section 4.2).<br />Interference with laboratory tests:<br />In general sugammadex does not interfere with laboratory tests, with the possible exception of<br />the serum progesterone assay. Interference with this test is observed at sugammadex plasma<br />concentrations of 100 microgram/mL (peak plasma level following 8 mg/kg bolus injection).<br />In a study in volunteers doses of 4 mg/kg and 16 mg/kg of sugammadex resulted in maximum<br />mean prolongations of aPTT by 17 and 22% respectively and of PT(INR) by 11 and 22%<br />respectively. These limited mean aPTT and PT(INR) prolongations were of short duration (&le; 30<br />minutes).<br />In in vitro experiments a pharmacodynamic interaction (aPTT and PT prolongation) was noted<br />with vitamin K antagonists, unfractionated heparin, low molecular weight heparinoids,<br />rivaroxaban and dabigatran (see section 4.4).<br />Paediatric population<br />No formal interaction studies have been performed. The above mentioned interactions for adults<br />and the warnings in section 4.4 should also be taken into account for the paediatric population.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy<br />For sugammadex no clinical data on exposed pregnancies are available.<br />Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy,<br />embryonic/foetal development, parturition or postnatal development.</p><p>Caution should be exercised when administering sugammadex to pregnant women.<br />Breast-feeding<br />It is unknown whether sugammadex is excreted in human breast milk. Animal studies have<br />shown excretion of sugammadex in breast milk. Oral absorption of cyclodextrins in general is<br />low and no effect on the suckling child is anticipated following a single dose to the breastfeeding<br />woman.<br />A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from<br />sugammadex therapy, taking into account the benefit of breast feeding for the child and the<br />benefit of therapy for the woman.<br />Fertility<br />The effects with sugammadex on human fertility have not been investigated. Animal studies to<br />evaluate fertility do not reveal harmful effects.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sudex has no known influence on the ability to drive and use machines</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Summary of the safety profile<br />Sudex is administered concomitantly with neuromuscular blocking agents and anaesthetics in<br />surgical patients. The causality of adverse events is therefore difficult to assess.<br />The most commonly reported adverse reactions in surgical patients were cough, airway<br />complication of anaesthesia, anaesthetic complications, procedural hypotension and procedural<br />complication (Common (&ge; 1/100 to &lt; 1/10)).<br />Table 2: Tabulated list of adverse reactions<br />The safety of sugammadex has been evaluated in 3,519 unique subjects across a pooled phase IIII<br />safety database. The following adverse reactions were reported in placebo controlled trials<br />where subjects received anaesthesia and/or neuromuscular blocking agents (1,078 subject<br />exposures to sugammadex versus 544 to placebo):<br />[Very common (&ge; 1/10), common (&ge; 1/100 to &lt; 1/10), uncommon (&ge; 1/1,000 to &lt; 1/100), rare (&ge;<br />1/10,000 to &lt; 1/1,000), very rare (&lt; 1/10,000)]</p><p>System organ class Frequencies Adverse reactions<br />(Preferred terms)<br />Immune system disorders Uncommon Drug hypersensitivity<br />reactions (see section 4.4)<br />Respiratory, thoracic and<br />mediastinal disorders<br />Common Cough<br />Injury, poisoning and<br />procedural complications<br />Common Airway complication of<br />anaesthesia<br />Anaesthetic complication<br />(see section 4.4)<br />Procedural hypotension<br />Procedural complication<br />Description of selected adverse reactions<br />Drug hypersensitivity reactions:<br />Hypersensitivity reactions, including anaphylaxis, have occurred in some patients and volunteers<br />(for information on volunteers, see Information on healthy volunteers below). In clinical trials of<br />surgical patients these reactions were reported uncommonly and for post-marketing reports the<br />frequency is unknown.<br />These reactions varied from isolated skin reactions to serious systemic reactions (i.e.<br />anaphylaxis, anaphylactic shock) and have occurred in patients with no prior exposure to<br />sugammadex.<br />Symptoms associated with these reactions can include: flushing, urticaria, erythematous rash,<br />(severe) hypotension, tachycardia, swelling of tongue, swelling of pharynx, bronchospasm and<br />pulmonary obstructive events. Severe hypersensitivity reactions can be fatal.<br />Airway complication of anaesthesia:<br />Airway complications of anaesthesia included bucking against the endotracheal tube, coughing,<br />mild bucking, arousal reaction during surgery, coughing during the anaesthetic procedure or<br />during surgery, or anaesthetic procedure-related spontaneous breath of patient.</p><p>Anaesthetic complication:<br />Anaesthetic complications, indicative of the restoration of neuromuscular function, include<br />movement of a limb or the body or coughing during the anaesthetic procedure or during surgery,<br />grimacing, or suckling on the endotracheal tube. See section 4.4 light anaesthesia.<br />Procedural complication:<br />Procedural complications included coughing, tachycardia, bradycardia, movement, and increase<br />in heart rate.<br />Marked bradycardia:<br />In post-marketing, isolated cases of marked bradycardia and bradycardia with cardiac arrest have<br />been observed within minutes after administration of sugammadex (see section 4.4).<br />Recurrence of neuromuscular blockade:<br />In clinical studies with subjects treated with rocuronium or vecuronium, where sugammadex was<br />administered using a dose labelled for the depth of neuromuscular blockade (N=2,022), an<br />incidence of 0.20% was observed for recurrence of neuromuscular blockade as based on<br />neuromuscular monitoring or clinical evidence (see section 4.4).<br />Information on healthy volunteers:<br />A randomised, double-blind study examined the incidence of drug hypersensitivity reactions in<br />healthy volunteers given up to 3 doses of placebo (N=76), sugammadex 4 mg/kg (N=151) or<br />sugammadex 16 mg/kg (N=148). Reports of suspected hypersensitivity were adjudicated by a<br />blinded committee. The incidence of adjudicated hypersensitivity was 1.3%, 6.6% and 9.5% in<br />the placebo, sugammadex 4 mg/kg and sugammadex 16 mg/kg groups, respectively. There were<br />no reports of anaphylaxis after placebo or sugammadex 4 mg/kg. There was a single case of<br />adjudicated anaphylaxis after the first dose of sugammadex 16 mg/kg (incidence 0.7%). There<br />was no evidence of increased frequency or severity of hypersensitivity with repeat dosing of<br />sugammadex.<br />In a previous study of similar design, there were three adjudicated cases of anaphylaxis, all after<br />sugammadex 16 mg/kg (incidence 2.0%).<br />In the Pooled Phase 1 database, AEs considered common (&ge; 1/100 to &lt; 1/10) or very common (&ge;<br />1/10) and more frequent among subjects treated with sugammadex than in the placebo group,</p><p>Module-1<br />include dysgeusia (10.1%), headache (6.7%), nausea (5.6%), urticaria (1.7%), pruritus (1.7%),<br />dizziness (1.6%), vomiting (1.2%) and abdominal pain (1.0%).<br />Additional information on special populations<br />Pulmonary patients:<br />In post-marketing data and in one dedicated clinical trial in patients with a history of pulmonary<br />complications, bronchospasm was reported as a possibly related adverse event. As with all<br />patients with a history of pulmonary complications the physician should be aware of the possible<br />occurrence of bronchospasm.<br />Paediatric population<br />A limited database suggests that the safety profile of sugammadex (up to 4 mg/kg) in paediatric<br />patients was similar to that in adults.<br />Morbidly obese patients<br />In one dedicated clinical trial in morbidly obese patients, the adverse reaction profile was<br />generally similar to the profile in adult patients in pooled Phase 1 to 3 studies (see Table 2).<br />Patients with severe systemic disease<br />In a trial in patients who were assessed as American Society of Anesthesiologists (ASA) Class 3<br />or 4 (patients with severe systemic disease or patients with severe systemic disease that is a<br />constant threat to life), the adverse reaction profile in these ASA Class 3 and 4 patients was<br />generally similar to that of adult patients in pooled Phase 1 to 3 studies (see Table 2). See section<br />5.1.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In clinical studies, 1 case of an accidental overdose with 40 mg/kg was reported without any<br />significant adverse reactions. In a human tolerance study sugammadex was administered in doses<br />up to 96 mg/kg. No dose related adverse events nor serious adverse events were reported.<br />Sugammadex can be removed using haemodialysis with a high flux filter, but not with a low flux<br />filter. Based upon clinical studies, sugammadex concentrations in plasma are reduced by up to<br />70% after a 3 to 6-hour dialysis session.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: all other therapeutic products, antidotes, ATC code: V03AB35<br />Mechanism of action:<br />Sugammadex is a modified gamma cyclodextrin which is a Selective Relaxant Binding Agent. It<br />forms a complex with the neuromuscular blocking agents rocuronium or vecuronium in plasma<br />and thereby reduces the amount of neuromuscular blocking agent available to bind to nicotinic<br />receptors in the neuromuscular junction. This results in the reversal of neuromuscular blockade<br />induced by rocuronium or vecuronium.</p><p>Pharmacodynamic effects:<br />Sugammadex has been administered in doses ranging from 0.5 mg/kg to 16 mg/kg in dose<br />response studies of rocuronium induced blockade (0.6, 0.9, 1.0 and 1.2 mg/kg rocuronium<br />bromide with and without maintenance doses) and vecuronium induced blockade (0.1 mg/kg<br />vecuronium bromide with or without maintenance doses) at different time points/depths of<br />blockade. In these studies a clear dose-response relationship was observed.<br />Clinical efficacy and safety:<br />Sugammadex can be administered at several time points after administration of rocuronium or<br />vecuronium bromide:<br />Routine reversal &ndash; deep neuromuscular blockade:<br />In a pivotal study patients were randomly assigned to the rocuronium or vecuronium group.<br />After the last dose of rocuronium or vecuronium, at 1-2 PTCs, 4 mg/kg sugammadex or 70<br />mcg/kg neostigmine was administered in a randomised order. The time from start of<br />administration of sugammadex or neostigmine to recovery of the T4/T1 ratio to 0.9 was:<br />Table 3: Time (minutes) from administration of sugammadex or neostigmine at deep<br />neuromuscular blockade (1-2 PTCs) after rocuronium or vecuronium to recovery of the<br />T4/T1 ratio to 0.9<br />Neuromuscular blocking<br />agent<br />Treatment regimen<br />Sugammadex (4 mg/kg) Neostigmine (70 mcg/kg)<br />Rocuronium<br />N 37 37<br />Median (minutes) 2.7 49.0<br />Range 1.2-16.1 13.3-145.7<br />Vecuronium<br />N 47 36<br />Median (minutes) 3.3 49.9<br />Range 1.4-68.4 46.0-312.7<br />Routine reversal &ndash; moderate neuromuscular blockade:</p><p>In another pivotal study patients were randomly assigned to the rocuronium or vecuronium<br />group. After the last dose of rocuronium or vecuronium, at the reappearance of T2, 2 mg/kg<br />sugammadex or 50 mcg/kg neostigmine was administered in a randomised order. The time from<br />start of administration of sugammadex or neostigmine to recovery of the T4/T1 ratio to 0.9 was:<br />Table 4: Time (minutes) from administration of sugammadex or neostigmine at<br />reappearance of T2 after rocuronium or vecuronium to recovery of the T4/T1 ratio to 0.9<br />Neuromuscular blocking<br />agent<br />Treatment regimen<br />Sugammadex (2 mg/kg) Neostigmine (50 mcg/kg)<br />Rocuronium<br />N 48 48<br />Median (minutes) 1.4 17.6<br />Range 0.9-5.4 3.7-106.9<br />Vecuronium<br />N 48 45<br />Median (minutes) 2.1 18.9<br />Range 1.2-64.2 2.9-76.2<br />Reversal by sugammadex of the neuromuscular blockade induced by rocuronium was compared<br />to the reversal by neostigmine of the neuromuscular blockade induced by cis-atracurium. At the<br />reappearance of T2 a dose of 2 mg/kg sugammadex or 50 mcg/kg neostigmine was administered.<br />Sugammadex provided faster reversal of neuromuscular blockade induced by rocuronium<br />compared to neostigmine reversal of neuromuscular blockade induced by cis-atracurium:<br />Table 5: Time (minutes) from administration of sugammadex or neostigmine at<br />reappearance of T2 after rocuronium or cis-atracurium to recovery of the T4/T1 ratio to 0.9<br />Neuromuscular blocking<br />agent<br />Treatment regimen<br />Rocuronium and<br />sugammadex (2 mg/kg)<br />Cis-atracurium and<br />neostigmine (50 mcg/kg)<br />N 34 39</p><p>Median (minutes) 1.9 7.2<br />Range 0.7-6.4 4.2-28.2<br />For immediate reversal:<br />The time to recovery from succinylcholine-induced neuromuscular blockade (1 mg/kg) was<br />compared with sugammadex (16 mg/kg, 3 minutes later) &ndash; induced recovery from rocuroniuminduced<br />neuromuscular blockade (1.2 mg/kg).<br />Table 6: Time (minutes) from administration of rocuronium and sugammadex or<br />succinylcholine to recovery of the T1 10%<br />Neuromuscular blocking<br />agent<br />Treatment regimen<br />Rocuronium and<br />sugammadex (16 mg/kg)<br />Succinylcholine (1 mg/kg)<br />N 55 55<br />Median (minutes) 4.2 7.1<br />Range 3.5-7.7 3.7-10.5<br />In a pooled analysis the following recovery times for 16 mg/kg sugammadex after 1.2 mg/kg<br />rocuronium bromide were reported:<br />Table 7: Time (minutes) from administration of sugammadex at 3 minutes after<br />rocuronium to recovery of the T4/T1 ratio to 0.9, 0.8 or 0.7<br />T4/T1 to 0.9 T4/T1 to 0.8 T4/T1 to 0.7<br />N 65 65 65<br />Median<br />(minutes)<br />1.5 1.3 1.1<br />Range 0.5-14.3 0.5-6.2 0.5-3.3<br />Renal impairment:<br />Two open label studies compared the efficacy and safety of sugammadex in surgical patients<br />with and without severe renal impairment. In one study, sugammadex was administered<br />following rocuronium induced blockade at 1-2 PTCs (4 mg/kg; N=68); in the other study,</p><p>sugammadex was administered at reappearance of T2 (2 mg/kg; N=30). Recovery from blockade<br />was modestly longer for patients with severe renal impairment relative to patients without renal<br />impairment. No residual neuromuscular blockade or recurrence of neuromuscular blockade was<br />reported for patients with severe renal impairment in these studies.<br />Morbidly obese patients:<br />A trial of 188 patients who were diagnosed as morbidly obese investigated the time to recovery<br />from moderate or deep neuromuscular blockade induced by rocuronium or vecuronium. Patients<br />received 2 mg/kg or 4 mg/kg sugammadex, as appropriate for level of block, dosed according to<br />either actual body weight or ideal body weight in random, double-blinded fashion. Pooled across<br />depth of block and neuromuscular blocking agent, the median time to recover to a train-of-four<br />(TOF) ratio &ge; 0.9 in patients dosed by actual body weight (1.8 minutes) was statistically<br />significantly faster (p &lt; 0.0001) compared to patients dosed by ideal body weight (3.3 minutes).<br />Patients with severe systemic disease:<br />A trial of 331 patients who were assessed as ASA Class 3 or 4 investigated the incidence of<br />treatment-emergent arrhythmias (sinus bradycardia, sinus tachycardia, or other cardiac<br />arrhythmias) after administration of sugammadex.<br />In patients receiving sugammadex (2 mg/kg, 4 mg/kg, or 16 mg/kg), the incidence of treatmentemergent<br />arrhythmias was generally similar to neostigmine (50 &mu;g/kg up to 5 mg maximum<br />dose) + glycopyrrolate (10 &mu;g/kg up to 1 mg maximum dose). The adverse reaction profile in<br />ASA Class 3 and 4 patients was generally similar to that of adult patients in pooled Phase 1 to 3<br />studies; therefore, no dosage adjustment is necessary. See section 4.8.<br />5.2 Pharmacokinetic properties<br />The sugammadex pharmacokinetic parameters were calculated from the total sum of noncomplex-<br />bound and complex-bound concentrations of sugammadex. Pharmacokinetic<br />parameters as clearance and volume of distribution are assumed to be the same for non-complexbound<br />and complex-bound sugammadex in anaesthetised subjects.<br />Distribution:<br />The observed steady-state volume of distribution of sugammadex is approximately 11 to 14 litres<br />in adult patients with normal renal function (based on conventional, non-compartmental</p><p>pharmacokinetic analysis). Neither sugammadex nor the complex of sugammadex and<br />rocuronium binds to plasma proteins or erythrocytes, as was shown in vitro using male human<br />plasma and whole blood. Sugammadex exhibits linear kinetics in the dosage range of 1 to 16<br />mg/kg when administered as an IV bolus dose.<br />Metabolism:<br />In preclinical and clinical studies no metabolites of sugammadex have been observed and only<br />renal excretion of the unchanged product was observed as the route of elimination.<br />Elimination:<br />In adult anaesthetized patients with normal renal function the elimination half-life (t1/2) of<br />sugammadex is about 2 hours and the estimated plasma clearance is about 88 mL/min. A mass<br />balance study demonstrated that &gt; 90% of the dose was excreted within 24 hours. 96% of the<br />dose was excreted in urine, of which at least 95% could be attributed to unchanged sugammadex.<br />Excretion via faeces or expired air was less than 0.02% of the dose. Administration of<br />sugammadex to healthy volunteers resulted in increased renal elimination of rocuronium in<br />complex.<br />Special populations:<br />Renal impairment and age:<br />In a pharmacokinetic study comparing patients with severe renal impairment to patients with<br />normal renal function, sugammadex levels in plasma were similar during the first hour after<br />dosing, and thereafter the levels decreased faster in the control group. Total exposure to<br />sugammadex was prolonged, leading to 17-fold higher exposure in patients with severe renal<br />impairment. Low concentrations of sugammadex are detectable for at least 48 hours post-dose in<br />patients with severe renal insufficiency.<br />In a second study comparing subjects with moderate or severe renal impairment to subjects with<br />normal renal function, sugammadex clearance progressively decreased and t1/2 was progressively<br />prolonged with declining renal function. Exposure was 2-fold and 5-fold higher in subjects with<br />moderate and severe renal impairment, respectively. Sugammadex concentrations were no longer<br />detectable beyond 7 days post-dose in subjects with severe renal insufficiency.</p><p>Table 8: A summary of sugammadex pharmacokinetic parameters stratified by age and<br />renal function is presented below:<br />Selected patient characteristics Mean Predicted PK parameters (CV%)<br />Demographics Renal function<br />Creatinine clearance<br />(mL/min)<br />Clearance<br />(mL/min)<br />Volume of<br />distribution at<br />steady state (L)<br />Elimination halflife<br />(hr)<br />Adult Normal<br />100 88 (22) 12 2 (21)<br />40 yrs Impaired Mild 50 51 (22) 13 4 (22)<br />75 kg<br />Moderate 30 31 (23) 14 6 (23)<br />Severe 10 9 (22) 14 19 (24)<br />Elderly Normal<br />80 75 (23) 12 2 (21)<br />75 yrs Impaired Mild 50 51 (24) 13 3 (22)<br />75 kg<br />Moderate 30 31 (23) 14 6 (23)<br />Severe 10 9 (22) 14 19 (23)<br />Adolescent Normal<br />95 77 (23) 9 2 (22)<br />15 yrs Impaired Mild 48 44 (23) 10 3 (22)<br />56 kg<br />Moderate 29 27 (22) 10 5 (23)<br />Severe 10 8 (21) 11 17 (23)<br />Child Normal<br />51 37 (22) 4 2 (20)<br />7 yrs Impaired Mild 26 19 (22) 4 3 (22)<br />23 kg<br />Moderate 15 11 (22) 4 5 (22)<br />Severe 5 3 (22) 5 20 (25)<br />CV=coefficient of variation<br />Gender:<br />No gender differences were observed.</p><p>Race:<br />In a study in healthy Japanese and Caucasian subjects no clinically relevant differences in<br />pharmacokinetic parameters were observed. Limited data does not indicate differences in<br />pharmacokinetic parameters in Black or African Americans.<br />Body weight:<br />Population pharmacokinetic analysis of adult and elderly patients showed no clinically relevant<br />relationship of clearance and volume of distribution with body weight.<br />Obesity:<br />In one clinical study in morbidly obese patients, sugammadex 2 mg/kg and 4 mg/kg was dosed<br />according to actual body weight (n=76) or ideal body weight (n=74). Sugammadex exposure<br />increased in a dose-dependent, linear manner following administration according to actual body<br />weight or ideal body weight. No clinically relevant differences in pharmacokinetic parameters<br />were observed between morbidly obese patients and the general population.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>5.2 Pharmacokinetic properties<br />The sugammadex pharmacokinetic parameters were calculated from the total sum of noncomplex-<br />bound and complex-bound concentrations of sugammadex. Pharmacokinetic<br />parameters as clearance and volume of distribution are assumed to be the same for non-complexbound<br />and complex-bound sugammadex in anaesthetised subjects.<br />Distribution:<br />The observed steady-state volume of distribution of sugammadex is approximately 11 to 14 litres<br />in adult patients with normal renal function (based on conventional, non-compartmental</p><p>pharmacokinetic analysis). Neither sugammadex nor the complex of sugammadex and<br />rocuronium binds to plasma proteins or erythrocytes, as was shown in vitro using male human<br />plasma and whole blood. Sugammadex exhibits linear kinetics in the dosage range of 1 to 16<br />mg/kg when administered as an IV bolus dose.<br />Metabolism:<br />In preclinical and clinical studies no metabolites of sugammadex have been observed and only<br />renal excretion of the unchanged product was observed as the route of elimination.<br />Elimination:<br />In adult anaesthetized patients with normal renal function the elimination half-life (t1/2) of<br />sugammadex is about 2 hours and the estimated plasma clearance is about 88 mL/min. A mass<br />balance study demonstrated that &gt; 90% of the dose was excreted within 24 hours. 96% of the<br />dose was excreted in urine, of which at least 95% could be attributed to unchanged sugammadex.<br />Excretion via faeces or expired air was less than 0.02% of the dose. Administration of<br />sugammadex to healthy volunteers resulted in increased renal elimination of rocuronium in<br />complex.<br />Special populations:<br />Renal impairment and age:<br />In a pharmacokinetic study comparing patients with severe renal impairment to patients with<br />normal renal function, sugammadex levels in plasma were similar during the first hour after<br />dosing, and thereafter the levels decreased faster in the control group. Total exposure to<br />sugammadex was prolonged, leading to 17-fold higher exposure in patients with severe renal<br />impairment. Low concentrations of sugammadex are detectable for at least 48 hours post-dose in<br />patients with severe renal insufficiency.<br />In a second study comparing subjects with moderate or severe renal impairment to subjects with<br />normal renal function, sugammadex clearance progressively decreased and t1/2 was progressively<br />prolonged with declining renal function. Exposure was 2-fold and 5-fold higher in subjects with<br />moderate and severe renal impairment, respectively. Sugammadex concentrations were no longer<br />detectable beyond 7 days post-dose in subjects with severe renal insufficiency.</p><p>Table 8: A summary of sugammadex pharmacokinetic parameters stratified by age and<br />renal function is presented below:<br />Selected patient characteristics Mean Predicted PK parameters (CV%)<br />Demographics Renal function<br />Creatinine clearance<br />(mL/min)<br />Clearance<br />(mL/min)<br />Volume of<br />distribution at<br />steady state (L)<br />Elimination halflife<br />(hr)<br />Adult Normal<br />100 88 (22) 12 2 (21)<br />40 yrs Impaired Mild 50 51 (22) 13 4 (22)<br />75 kg<br />Moderate 30 31 (23) 14 6 (23)<br />Severe 10 9 (22) 14 19 (24)<br />Elderly Normal<br />80 75 (23) 12 2 (21)<br />75 yrs Impaired Mild 50 51 (24) 13 3 (22)<br />75 kg<br />Moderate 30 31 (23) 14 6 (23)<br />Severe 10 9 (22) 14 19 (23)<br />Adolescent Normal<br />95 77 (23) 9 2 (22)<br />15 yrs Impaired Mild 48 44 (23) 10 3 (22)<br />56 kg<br />Moderate 29 27 (22) 10 5 (23)<br />Severe 10 8 (21) 11 17 (23)<br />Child Normal<br />51 37 (22) 4 2 (20)<br />7 yrs Impaired Mild 26 19 (22) 4 3 (22)<br />23 kg<br />Moderate 15 11 (22) 4 5 (22)<br />Severe 5 3 (22) 5 20 (25)<br />CV=coefficient of variation<br />Gender:<br />No gender differences were observed.</p><p>Race:<br />In a study in healthy Japanese and Caucasian subjects no clinically relevant differences in<br />pharmacokinetic parameters were observed. Limited data does not indicate differences in<br />pharmacokinetic parameters in Black or African Americans.<br />Body weight:<br />Population pharmacokinetic analysis of adult and elderly patients showed no clinically relevant<br />relationship of clearance and volume of distribution with body weight.<br />Obesity:<br />In one clinical study in morbidly obese patients, sugammadex 2 mg/kg and 4 mg/kg was dosed<br />according to actual body weight (n=76) or ideal body weight (n=74). Sugammadex exposure<br />increased in a dose-dependent, linear manner following administration according to actual body<br />weight or ideal body weight. No clinically relevant differences in pharmacokinetic parameters<br />were observed between morbidly obese patients and the general population.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Preclinical data reveal no special hazard for humans based on conventional studies of safety<br />pharmacology, repeated dose toxicity, genotoxicity potential, and toxicity to reproduction, local<br />tolerance or compatibility with blood.<br />Sugammadex is rapidly cleared in preclinical species, although residual sugammadex was<br />observed in bone and teeth of juvenile rats. Preclinical studies in young adult and mature rats<br />demonstrate that sugammadex does not adversely affect tooth colour or bone quality, bone<br />structure, or bone metabolism. Sugammadex has no effects on fracture repair and remodelling of<br />bone.<br />6. Pharmaceutical</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sodium Hydroxide (to adjust pH), Hydrochloric acid (to adjust pH) and water for injection</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product must not be mixed with other medicinal products except those mentioned<br />in section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months
After first opening and dilution chemical and physical in-use stability has been demonstrated for
48 hours at 2°C to 25°C. From a microbiological point of view, the diluted product should be
used immediately. If not used immediately, in-use storage times and conditions prior to use are
the responsibility of the user and would normally not be longer than 24 hours at 2°C to 8°C,
unless dilution has taken place in controlled and validated aseptic conditions.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.<br />Do not freeze.<br />Keep the vial in the outer carton in order to protect from light.<br />For storage conditions of the diluted medicinal product, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Vial pack</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>can be injected into the intravenous line of a running infusion with the following<br />intravenous solutions: sodium chloride 9 mg/mL (0.9%), glucose 50 mg/mL (5%), sodium<br />chloride 4.5 mg/mL (0.45%) and glucose 25 mg/mL (2.5%), Ringers lactate solution, Ringers<br />solution, glucose 50 mg/mL (5%) in sodium chloride 9 mg/mL (0.9%).<br />The infusion line should be adequately flushed (e.g., with 0.9% sodium chloride) between<br />administration of Sudex and other drugs.<br />Use in the paediatric population<br />For paediatric patients Sudex can be diluted using sodium chloride 9 mg/mL (0.9%) to a<br />concentration of 10 mg/mL.<br />Any unused medicinal product or waste material should be disposed of in accordance with local<br />requirements.<br />Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how<br />to throw away medicines you no longer use. These measures will help protect the environment</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Amarox Industrial Company,
Aljameah Street, Malaz quarter,
Riyadh 12929, Saudi Arabia
Tel: +966 112268850
Manufacture: ASPIRO Pharma Limited, Telangana, India.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                January– 2024.
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>